Literature DB >> 6751834

Tizanidine in the treatment of spasticity.

P M Newman, M Nogues, P K Newman, D Weightman, P Hudgson.   

Abstract

A double-blind crossover trial compared tizanidine with baclofen in 36 patients with spasticity. Tizanidine appeared to reduce lower limb spasticity more effectively and to have fewer side effects, but no statistically significant differences emerged when the two drugs were compared. An additional open study of tizanidine confirmed the beneficial action in a selected minority of patients with spasticity. This drug may have an important role in the management of spasticity, but further studies are required.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6751834     DOI： 10.1007/bf01061374

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  6 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

3.  [Clinical experiences with a new muscle relaxant (DS 103-282 Sandoz) (author's transl)].

Authors:  E Ringwald; S J Campean; F Gerstenbrand; A Lorincz; P Lörincz; H P Ludin
Journal:  Nervenarzt       Date:  1977-07       Impact factor: 1.214

4.  A rating system for neurological impairment in multiple sclerosis.

Authors:  E Pedersen
Journal:  Acta Neurol Scand Suppl       Date:  1965

5.  The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.

Authors:  A C Sayers; H R Bürki; E Eichenberger
Journal:  Arzneimittelforschung       Date:  1980

6.  Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

Authors:  N Hassan; D L McLellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-12       Impact factor: 10.154
  6 in total
  9 in total

Review 1.  Silperisone: a centrally acting muscle relaxant.

Authors:  Sándor Farkas
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Trends in the pathophysiology and pharmacotherapy of spasticity.

Authors:  J Noth
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

3.  The effect of intrathecal baclofen on electrical muscle activity in spasticity.

Authors:  H Müller; J Zierski; D Dralle; U Börner; O Hoffmann
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

Review 4.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

Review 5.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

6.  Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.

Authors:  David N Rushton; Adam C Lloyd; Pippa M Anderson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 8.  Drugs used to treat spasticity.

Authors:  M Kita; D E Goodkin
Journal:  Drugs       Date:  2000-03       Impact factor: 11.431

9.  Thoracic 9 Spinal Transection-Induced Model of Muscle Spasticity in the Rat: A Systematic Electrophysiological and Histopathological Characterization.

Authors:  Jose A Corleto; Mariana Bravo-Hernández; Kota Kamizato; Osamu Kakinohana; Camila Santucci; Michael R Navarro; Oleksandr Platoshyn; Dasa Cizkova; Nadezda Lukacova; Julian Taylor; Martin Marsala
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.